Mds 1
•Download as PPTX, PDF•
1 like•176 views
Myelodysplastic syndrome is a clonal hematopoietic stem cell disorder characterized by cytopenias, dysplasia of blood cells, and risk of progression to acute leukemia. It occurs most commonly in elderly patients and is caused by ineffective hematopoiesis where blood cells produced in the bone marrow are abnormal and destroyed early. The disease involves dysplasia of the myeloid, erythroid, and megakaryocytic cell lines and is classified based on the percentage of blasts and cytopenias seen in the bone marrow and peripheral blood.
Report
Share
Report
Share
Recommended
Myelodysplastic syndrome
The document discusses myelodysplastic syndromes (MDS), a group of stem cell malignancies characterized by ineffective hematopoiesis, cytopenias, and a risk of progression to acute myeloid leukemia. MDS arises from clonal mutations in hematopoietic stem cells and most commonly affects older adults. Diagnosis involves blood tests, bone marrow biopsy and aspiration showing dysplastic changes, and cytogenetic analysis to identify chromosomal abnormalities associated with prognosis. MDS ranges from indolent to aggressive disease depending on factors like karyotype and bone marrow blast percentage.
Myelodysplastic Syndrome
This document discusses Myelodysplastic Syndromes (MDS), including definitions, classification systems, predisposing factors, cytogenetic abnormalities, theories of pathophysiology, clinical manifestations, laboratory/pathology findings, and morphological abnormalities. Key points:
- MDS are clonal stem cell disorders characterized by ineffective hematopoiesis leading to cytopenias from defects in maturation. There have been many historical names and classification schemes, now defined by WHO.
- Predisposing factors include aging, genetic syndromes, chemotherapy/radiation, and environmental exposures. Cytogenetic abnormalities impact prognosis.
- Pathophysiology involves genetic/epigenetic changes, telomere dysfunction, altered micro
myelodysplastic syndrome
This document discusses myelodysplastic syndrome (MDS), a group of stem cell diseases characterized by cytopenias, dysplasia, and risk of acute myeloid leukemia. It covers the epidemiology, etiology, pathophysiology, genetics, classification systems including FAB and WHO, clinical features, laboratory findings, bone marrow findings, immunophenotyping, and evaluation of patients with suspected MDS. Key points include that MDS occurs mainly in older adults, can be de novo or therapy-related, involves clonal stem cell mutations, and classifications are based on peripheral blood, bone marrow blasts, and cytogenetics.
Myelodysplastic syndrome according to WHO 2016
The document defines myelodysplastic syndromes as a group of clonal stem cell diseases characterized by cytopenia, dysplasia in one or more myeloid lineages, ineffective hematopoiesis, recurrent genetic abnormalities, and an increased risk of developing acute myeloid leukemia. It discusses the epidemiology, etiology, pathophysiology, cytogenetics, morphological features, clinical features, WHO classification, differential diagnosis, variants, immunophenotyping, management, and prognosis of MDS. The document provides details on the definition, evaluation, classification, genetic abnormalities, and clinical manifestations of myelodysplastic syndromes.
Mielodisplasia
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders characterized by ineffective hematopoiesis and peripheral cytopenias. MDS often affects older patients and can progress to acute leukemia. The pathophysiology involves initiating lesions in stem cells that give rise to clones with mutations promoting additional genetic changes and ineffective hematopoiesis. Clinical features include cytopenias and dysplastic changes in the bone marrow. MDS is classified according to the French-American-British system based on peripheral blood and bone marrow findings. Prognosis is assessed using the International Prognostic Scoring System. Treatment options include supportive care, stem cell transplantation, cytokine therapy, chemotherapy, and immunosuppression
Myelodysplastic Syndrome
Dr. Kaushalya M K discusses myelodysplastic syndromes (MDS) in the document. Some key points:
1. MDS is a group of clonal hematopoietic stem cell diseases characterized by cytopenia, dysplasia, ineffective hematopoiesis, and increased risk of acute myeloid leukemia.
2. Risk factors for MDS include aging, environmental exposures like smoking and radiation, genetic disorders, and prior chemotherapy or radiation therapy.
3. Symptoms are related to cytopenias and include fatigue, infections, bleeding, and shortness of breath. Diagnosis involves blood tests, bone marrow biopsy, and cytogenetic analysis.
4. Treatment
Myelodysplastic syndrome
Myelodysplastic syndrome (MDS) is a group of hematologic disorders characterized by ineffective hematopoiesis and maturation defects leading to pancytopenia. MDS can be classified according to percentage of blasts and ringed sideroblasts. Common features include peripheral cytopenias, dysplastic changes in the bone marrow, and risk of progression to acute leukemia. Treatment involves supportive care such as blood transfusions, and allogeneic bone marrow transplant may provide long-term remission for some patients.
Myelodysplastic syndromes
Myelodysplastic syndromes (MDS) are a group of stem cell disorders characterized by ineffective hematopoiesis and a risk of transforming to acute myeloid leukemia. MDS can be primary or secondary to chemotherapy/radiation. The bone marrow shows dysplastic changes in the myeloid lineages. MDS is diagnosed based on blood and bone marrow morphology and cytogenetics. Prognosis depends on blast count, cytopenias, and chromosomal abnormalities, with higher risk features indicating worse outcomes like shorter survival times or faster progression to AML. Treatment options are limited and include stem cell transplantation in younger patients or supportive care in older patients.
Recommended
Myelodysplastic syndrome
The document discusses myelodysplastic syndromes (MDS), a group of stem cell malignancies characterized by ineffective hematopoiesis, cytopenias, and a risk of progression to acute myeloid leukemia. MDS arises from clonal mutations in hematopoietic stem cells and most commonly affects older adults. Diagnosis involves blood tests, bone marrow biopsy and aspiration showing dysplastic changes, and cytogenetic analysis to identify chromosomal abnormalities associated with prognosis. MDS ranges from indolent to aggressive disease depending on factors like karyotype and bone marrow blast percentage.
Myelodysplastic Syndrome
This document discusses Myelodysplastic Syndromes (MDS), including definitions, classification systems, predisposing factors, cytogenetic abnormalities, theories of pathophysiology, clinical manifestations, laboratory/pathology findings, and morphological abnormalities. Key points:
- MDS are clonal stem cell disorders characterized by ineffective hematopoiesis leading to cytopenias from defects in maturation. There have been many historical names and classification schemes, now defined by WHO.
- Predisposing factors include aging, genetic syndromes, chemotherapy/radiation, and environmental exposures. Cytogenetic abnormalities impact prognosis.
- Pathophysiology involves genetic/epigenetic changes, telomere dysfunction, altered micro
myelodysplastic syndrome
This document discusses myelodysplastic syndrome (MDS), a group of stem cell diseases characterized by cytopenias, dysplasia, and risk of acute myeloid leukemia. It covers the epidemiology, etiology, pathophysiology, genetics, classification systems including FAB and WHO, clinical features, laboratory findings, bone marrow findings, immunophenotyping, and evaluation of patients with suspected MDS. Key points include that MDS occurs mainly in older adults, can be de novo or therapy-related, involves clonal stem cell mutations, and classifications are based on peripheral blood, bone marrow blasts, and cytogenetics.
Myelodysplastic syndrome according to WHO 2016
The document defines myelodysplastic syndromes as a group of clonal stem cell diseases characterized by cytopenia, dysplasia in one or more myeloid lineages, ineffective hematopoiesis, recurrent genetic abnormalities, and an increased risk of developing acute myeloid leukemia. It discusses the epidemiology, etiology, pathophysiology, cytogenetics, morphological features, clinical features, WHO classification, differential diagnosis, variants, immunophenotyping, management, and prognosis of MDS. The document provides details on the definition, evaluation, classification, genetic abnormalities, and clinical manifestations of myelodysplastic syndromes.
Mielodisplasia
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders characterized by ineffective hematopoiesis and peripheral cytopenias. MDS often affects older patients and can progress to acute leukemia. The pathophysiology involves initiating lesions in stem cells that give rise to clones with mutations promoting additional genetic changes and ineffective hematopoiesis. Clinical features include cytopenias and dysplastic changes in the bone marrow. MDS is classified according to the French-American-British system based on peripheral blood and bone marrow findings. Prognosis is assessed using the International Prognostic Scoring System. Treatment options include supportive care, stem cell transplantation, cytokine therapy, chemotherapy, and immunosuppression
Myelodysplastic Syndrome
Dr. Kaushalya M K discusses myelodysplastic syndromes (MDS) in the document. Some key points:
1. MDS is a group of clonal hematopoietic stem cell diseases characterized by cytopenia, dysplasia, ineffective hematopoiesis, and increased risk of acute myeloid leukemia.
2. Risk factors for MDS include aging, environmental exposures like smoking and radiation, genetic disorders, and prior chemotherapy or radiation therapy.
3. Symptoms are related to cytopenias and include fatigue, infections, bleeding, and shortness of breath. Diagnosis involves blood tests, bone marrow biopsy, and cytogenetic analysis.
4. Treatment
Myelodysplastic syndrome
Myelodysplastic syndrome (MDS) is a group of hematologic disorders characterized by ineffective hematopoiesis and maturation defects leading to pancytopenia. MDS can be classified according to percentage of blasts and ringed sideroblasts. Common features include peripheral cytopenias, dysplastic changes in the bone marrow, and risk of progression to acute leukemia. Treatment involves supportive care such as blood transfusions, and allogeneic bone marrow transplant may provide long-term remission for some patients.
Myelodysplastic syndromes
Myelodysplastic syndromes (MDS) are a group of stem cell disorders characterized by ineffective hematopoiesis and a risk of transforming to acute myeloid leukemia. MDS can be primary or secondary to chemotherapy/radiation. The bone marrow shows dysplastic changes in the myeloid lineages. MDS is diagnosed based on blood and bone marrow morphology and cytogenetics. Prognosis depends on blast count, cytopenias, and chromosomal abnormalities, with higher risk features indicating worse outcomes like shorter survival times or faster progression to AML. Treatment options are limited and include stem cell transplantation in younger patients or supportive care in older patients.
Mds
Myelodysplastic syndrome (MDS) is a group of bone marrow disorders where the bone marrow fails to produce mature and healthy blood cells. This leads to low blood cell counts and a risk of developing acute myeloid leukemia. MDS is characterized by dysplasia in one or more cell lines and subgroups are defined by specific percentages of blasts in the bone marrow and blood. Common subgroups include refractory anemia, refractory anemia with ringed sideroblasts, and refractory anemia with excess blasts. Chromosomal abnormalities are present in many cases of MDS and help define prognosis.
Mds
Myelodysplasia, also known as myelodysplastic syndrome (MDS), is a heterogeneous group of hematopoietic stem cell disorders that results in ineffective hematopoiesis and cytopenias. MDS is primarily seen in elderly patients and has a risk of progression to acute myeloid leukemia. Characteristic features include increased marrow proliferation, failure of stem cells to differentiate, and increased marrow apoptosis. Cytogenetic abnormalities are detected in 30-70% of patients and correlate with risk of progression. Treatment may include stem cell transplant, DNA methyltransferase inhibitors, immunotherapy, and chemotherapy.
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and peripheral cytopenias. The natural history ranges from indolent forms lasting years to rapid evolution to acute myeloid leukemia (AML). MDS is classified by the French-American-British (FAB) system and World Health Organization (WHO) based on blast percentage and cytogenetic features. The International Prognostic Scoring System (IPSS) further stratifies patients by risk of progression or death. Known molecular abnormalities include mutations in genes such as TP53, RAS, and FMS.
V_Hematology_Forum_Prof_Gujral
Myelodysplastic Syndrome (MDS) is a heterogeneous group of clonal hematopoietic stem cell disorders characterized by cytopenias, dysplastic changes in one or more myeloid cell lines, and a risk of progression to acute myeloid leukemia. MDS is not a single disease, but rather a spectrum of related disorders. Diagnosis involves evaluation of blood counts, peripheral smear, bone marrow aspirate/biopsy along with cytogenetics and molecular testing to identify abnormalities. Prognosis varies from indolent to high-risk of transformation based on the WHO classification which considers disease subtype, blast percentage, and cytogenetic risk factors.
Mds n mps
MDS and myeloproliferative disorders are heterogeneous groups of clonal stem cell disorders characterized by ineffective or excessive blood cell production. MDS involves dysplastic and ineffective hematopoiesis that can progress to acute leukemia, while myeloproliferative disorders feature overgrowth of one or more myeloid cell lines. Key disorders discussed include MDS, polycythemia vera involving excessive red blood cell production, essential thrombocytosis with marked thrombocytosis, myelofibrosis with bone marrow fibrosis, and chronic myeloid leukemia characterized by the Philadelphia chromosome translocation. Diagnosis and classification of these disorders has evolved with new genetic and molecular testing.
Myelodysplastic syndrome
Myelodysplastic Syndrome - Haematology , Pathology
Reference -Wintrobe , Robbins, Tejinder Singh Haematology
Refractory anemia case report mds
A case report of MDS presenting as refractory anemia, followed by overview of treatment of MDS and comparison of hypomethylating agents (HMAs)
Myelodysplastic syndrome (MDS)
This document describes myelodysplastic syndromes (MDS), a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to peripheral blood cytopenias. It discusses the history of MDS classification including the French-American-British (FAB) and World Health Organization (WHO) systems. Key features of the different MDS subtypes are outlined along with associated cytogenetic abnormalities, predisposing factors, theories of pathophysiology, clinical manifestations, and diagnostic evaluation.
Myelodysplastic Syndromes ppt
This document provides an overview of myelodysplastic syndrome (MDS). It discusses the history and changing definitions of MDS, current WHO classification, clinical features, pathogenesis involving genetic and epigenetic abnormalities, dysplastic changes seen in the bone marrow, and identification of blast cells. MDS is a heterogenous stem cell disorder characterized by cytopenias, dysplasia, and increased risk of acute myeloid leukemia. The disease results from acquired mutations in hematopoietic stem/progenitor cells and involves dysregulated apoptosis, ineffective hematopoiesis, and genetic and epigenetic changes.
Myelodysplastic Syndrome
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal stem cell disorders where the bone marrow cannot produce blood cells effectively. Patients present with varying degrees of cytopenias. MDS may progress to acute leukemia. The WHO classification system recognizes subtypes based on blast percentage and cytogenetics that provide prognostic information. MDS results from genetic mutations and epigenetic changes in hematopoietic stem cells. Presenting signs include anemia, infections, and bleeding due to cytopenias. Evaluation involves blood tests, bone marrow aspiration/biopsy, and cytogenetics. Refractory cytopenia with unilineage dysplasia is the most common subtype.
Myelodysplastic Syndrome
Myelodysplastic syndrome is a disorder where stem cells in the bone marrow do not mature normally, resulting in reduced numbers of one or more types of blood cells. It most commonly arises in two settings - idiopathic MDS in those over 50 years old, or therapy-related MDS in patients who received previous chemotherapy or radiation treatment. Common symptoms include fatigue and increased risk of infection due to low blood cell counts. Prognosis depends on the percentage of immature blood cells in the bone marrow, with higher percentages associated with greater risk of progression to acute myeloid leukemia and shorter survival times.
Refreactory anemia
Refractory anemia is a subtype of myelodysplastic syndrome characterized by non-responsiveness to conventional anemia treatment. It is defined by less than 5% blasts in the bone marrow and less than 1% in the peripheral blood. Refractory anemia involves dysplasia primarily affecting the erythroid lineage. Evaluation includes blood counts, peripheral smear, bone marrow biopsy and cytogenetic testing to confirm the diagnosis and guide prognosis. Management focuses on treating the anemia and related symptoms.
Myelodysplastic Syndrome
By Doctor Okto. Vivid decription on Introduction, classification, diagnosis, management, complications of Myelodysplastic syndrome.
Mds csbrp
Myelodysplastic syndromes (MDS) are a group of hematological disorders characterized by ineffective hematopoiesis, dysplasia in the bone marrow, and a high risk of progression to acute myeloid leukemia. The key features of MDS include increased proliferation but failed differentiation of stem cells in the bone marrow, resulting in cytopenias. Many MDS cases progress to acute leukemia. Treatment options are limited and depend on individual risk factors, with median survival ranging from over 5 years in low risk cases to under 2 years in high risk MDS.
Myelodysplastic syndrome by dr narmada
Myelodysplastic syndromes (MDS) are a group of bone marrow disorders characterized by ineffective blood cell production and shortages of normal blood cells. In MDS, the bone marrow cannot produce mature and fully functional blood cells. This leads to low blood cell counts and symptoms like anemia, fatigue, and infections. MDS has several subtypes classified by the FAB system based on blood cell dysplasia and percentage of blasts in the bone marrow, with some subtypes having a higher risk of progression to acute leukemia. Chromosomal abnormalities are common in MDS and help determine prognosis.
Myelodysplastic syndromes
Myelodysplastic syndromes are a group of myeloid disorders characterized by peripheral blood cytopenias and dysplasia in bone marrow cells. MDS results from clonal stem cell disorders that impair differentiation, causing low blood cell counts and risk of acute myeloid leukemia. The disease mainly affects the elderly and risk factors include genetic mutations, toxic exposures, and certain genetic syndromes. Diagnosis involves blood tests showing low counts of one or more cell types and bone marrow biopsy demonstrating dysplastic changes. Prognosis ranges from long-term survival to rapid progression; treatment focuses on supportive care like transfusions as well as hypomethylating agents or stem cell transplantation in high-risk cases.
Mds
Myelodisplastic syndrome
amirhossein heydarian
Iran- shahid beheshti medical university
www.amirhossein.heydarian@yahoo.com
Mds&mds mpn
This document provides an overview of myelodysplastic syndromes (MDS). MDS are a heterogeneous group of stem cell disorders characterized by cytopenias, dysplastic bone marrow, and risk of leukemia development. The FAB classification from 1982 and revised WHO classification from 2001 are discussed. Key points include defining the subtypes of MDS (such as refractory anemia or RA with excess blasts), associated features (including ring sideroblasts and cytogenetic abnormalities), and diagnostic criteria based on blood and bone marrow findings. In particular, the document highlights the isolated del(5q) abnormality associated with 5q- syndrome.
Myeloproliferative disorders
i prepared this from different references, but majority is from Davidson internal medicine and Uptodate
Myeloproliferative disorders
The document discusses various myeloproliferative neoplasms (MPNs) including classic MPNs such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis as well as atypical MPNs. It provides details on the diagnostic criteria, signs and symptoms, genetic mutations involved, and treatment approaches for these different MPNs. Chronic myelogenous leukemia is also examined as it represents a distinct MPN characterized by the Philadelphia chromosome genetic abnormality.
Pre leukemia MDS
The document discusses several pre-leukemic disorders and congenital defects that can progress to acute myeloid leukemia (AML) if not treated. These include myelodysplastic syndrome (MDS), marrow failure syndromes like aplastic anemia, and genetic conditions like Fanconi anemia, dyskeratosis congenita, and Shwachman-Diamond syndrome. MDS is characterized by dysplastic and ineffective hematopoiesis leading to cytopenias. Fanconi anemia results from a DNA repair defect and patients have a high risk of developing AML. Dyskeratosis congenita causes bone marrow failure below age 20 due to telomere dysfunction. Treatment options discussed include hematopoietic
MYELODYSPLASTICSYNDROMES.ppt
The myelodysplastic syndromes (MDS) are a group of diseases characterized by bone marrow failure and abnormalities in the appearance of blood cells. MDS results from mutations in bone marrow stem cells that impair differentiation and increase cell death. While some patients with MDS develop acute leukemia, most do not. MDS is diagnosed based on peripheral blood cytopenias and characteristic dysplastic changes seen in the bone marrow, including ring sideroblasts, hypogranular neutrophils, and micromegakaryocytes. Cytogenetic abnormalities are also important for diagnosis and prognosis. Morphologic evaluation remains key for diagnosis of MDS.
More Related Content
What's hot
Mds
Myelodysplastic syndrome (MDS) is a group of bone marrow disorders where the bone marrow fails to produce mature and healthy blood cells. This leads to low blood cell counts and a risk of developing acute myeloid leukemia. MDS is characterized by dysplasia in one or more cell lines and subgroups are defined by specific percentages of blasts in the bone marrow and blood. Common subgroups include refractory anemia, refractory anemia with ringed sideroblasts, and refractory anemia with excess blasts. Chromosomal abnormalities are present in many cases of MDS and help define prognosis.
Mds
Myelodysplasia, also known as myelodysplastic syndrome (MDS), is a heterogeneous group of hematopoietic stem cell disorders that results in ineffective hematopoiesis and cytopenias. MDS is primarily seen in elderly patients and has a risk of progression to acute myeloid leukemia. Characteristic features include increased marrow proliferation, failure of stem cells to differentiate, and increased marrow apoptosis. Cytogenetic abnormalities are detected in 30-70% of patients and correlate with risk of progression. Treatment may include stem cell transplant, DNA methyltransferase inhibitors, immunotherapy, and chemotherapy.
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and peripheral cytopenias. The natural history ranges from indolent forms lasting years to rapid evolution to acute myeloid leukemia (AML). MDS is classified by the French-American-British (FAB) system and World Health Organization (WHO) based on blast percentage and cytogenetic features. The International Prognostic Scoring System (IPSS) further stratifies patients by risk of progression or death. Known molecular abnormalities include mutations in genes such as TP53, RAS, and FMS.
V_Hematology_Forum_Prof_Gujral
Myelodysplastic Syndrome (MDS) is a heterogeneous group of clonal hematopoietic stem cell disorders characterized by cytopenias, dysplastic changes in one or more myeloid cell lines, and a risk of progression to acute myeloid leukemia. MDS is not a single disease, but rather a spectrum of related disorders. Diagnosis involves evaluation of blood counts, peripheral smear, bone marrow aspirate/biopsy along with cytogenetics and molecular testing to identify abnormalities. Prognosis varies from indolent to high-risk of transformation based on the WHO classification which considers disease subtype, blast percentage, and cytogenetic risk factors.
Mds n mps
MDS and myeloproliferative disorders are heterogeneous groups of clonal stem cell disorders characterized by ineffective or excessive blood cell production. MDS involves dysplastic and ineffective hematopoiesis that can progress to acute leukemia, while myeloproliferative disorders feature overgrowth of one or more myeloid cell lines. Key disorders discussed include MDS, polycythemia vera involving excessive red blood cell production, essential thrombocytosis with marked thrombocytosis, myelofibrosis with bone marrow fibrosis, and chronic myeloid leukemia characterized by the Philadelphia chromosome translocation. Diagnosis and classification of these disorders has evolved with new genetic and molecular testing.
Myelodysplastic syndrome
Myelodysplastic Syndrome - Haematology , Pathology
Reference -Wintrobe , Robbins, Tejinder Singh Haematology
Refractory anemia case report mds
A case report of MDS presenting as refractory anemia, followed by overview of treatment of MDS and comparison of hypomethylating agents (HMAs)
Myelodysplastic syndrome (MDS)
This document describes myelodysplastic syndromes (MDS), a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to peripheral blood cytopenias. It discusses the history of MDS classification including the French-American-British (FAB) and World Health Organization (WHO) systems. Key features of the different MDS subtypes are outlined along with associated cytogenetic abnormalities, predisposing factors, theories of pathophysiology, clinical manifestations, and diagnostic evaluation.
Myelodysplastic Syndromes ppt
This document provides an overview of myelodysplastic syndrome (MDS). It discusses the history and changing definitions of MDS, current WHO classification, clinical features, pathogenesis involving genetic and epigenetic abnormalities, dysplastic changes seen in the bone marrow, and identification of blast cells. MDS is a heterogenous stem cell disorder characterized by cytopenias, dysplasia, and increased risk of acute myeloid leukemia. The disease results from acquired mutations in hematopoietic stem/progenitor cells and involves dysregulated apoptosis, ineffective hematopoiesis, and genetic and epigenetic changes.
Myelodysplastic Syndrome
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal stem cell disorders where the bone marrow cannot produce blood cells effectively. Patients present with varying degrees of cytopenias. MDS may progress to acute leukemia. The WHO classification system recognizes subtypes based on blast percentage and cytogenetics that provide prognostic information. MDS results from genetic mutations and epigenetic changes in hematopoietic stem cells. Presenting signs include anemia, infections, and bleeding due to cytopenias. Evaluation involves blood tests, bone marrow aspiration/biopsy, and cytogenetics. Refractory cytopenia with unilineage dysplasia is the most common subtype.
Myelodysplastic Syndrome
Myelodysplastic syndrome is a disorder where stem cells in the bone marrow do not mature normally, resulting in reduced numbers of one or more types of blood cells. It most commonly arises in two settings - idiopathic MDS in those over 50 years old, or therapy-related MDS in patients who received previous chemotherapy or radiation treatment. Common symptoms include fatigue and increased risk of infection due to low blood cell counts. Prognosis depends on the percentage of immature blood cells in the bone marrow, with higher percentages associated with greater risk of progression to acute myeloid leukemia and shorter survival times.
Refreactory anemia
Refractory anemia is a subtype of myelodysplastic syndrome characterized by non-responsiveness to conventional anemia treatment. It is defined by less than 5% blasts in the bone marrow and less than 1% in the peripheral blood. Refractory anemia involves dysplasia primarily affecting the erythroid lineage. Evaluation includes blood counts, peripheral smear, bone marrow biopsy and cytogenetic testing to confirm the diagnosis and guide prognosis. Management focuses on treating the anemia and related symptoms.
Myelodysplastic Syndrome
By Doctor Okto. Vivid decription on Introduction, classification, diagnosis, management, complications of Myelodysplastic syndrome.
Mds csbrp
Myelodysplastic syndromes (MDS) are a group of hematological disorders characterized by ineffective hematopoiesis, dysplasia in the bone marrow, and a high risk of progression to acute myeloid leukemia. The key features of MDS include increased proliferation but failed differentiation of stem cells in the bone marrow, resulting in cytopenias. Many MDS cases progress to acute leukemia. Treatment options are limited and depend on individual risk factors, with median survival ranging from over 5 years in low risk cases to under 2 years in high risk MDS.
Myelodysplastic syndrome by dr narmada
Myelodysplastic syndromes (MDS) are a group of bone marrow disorders characterized by ineffective blood cell production and shortages of normal blood cells. In MDS, the bone marrow cannot produce mature and fully functional blood cells. This leads to low blood cell counts and symptoms like anemia, fatigue, and infections. MDS has several subtypes classified by the FAB system based on blood cell dysplasia and percentage of blasts in the bone marrow, with some subtypes having a higher risk of progression to acute leukemia. Chromosomal abnormalities are common in MDS and help determine prognosis.
Myelodysplastic syndromes
Myelodysplastic syndromes are a group of myeloid disorders characterized by peripheral blood cytopenias and dysplasia in bone marrow cells. MDS results from clonal stem cell disorders that impair differentiation, causing low blood cell counts and risk of acute myeloid leukemia. The disease mainly affects the elderly and risk factors include genetic mutations, toxic exposures, and certain genetic syndromes. Diagnosis involves blood tests showing low counts of one or more cell types and bone marrow biopsy demonstrating dysplastic changes. Prognosis ranges from long-term survival to rapid progression; treatment focuses on supportive care like transfusions as well as hypomethylating agents or stem cell transplantation in high-risk cases.
Mds
Myelodisplastic syndrome
amirhossein heydarian
Iran- shahid beheshti medical university
www.amirhossein.heydarian@yahoo.com
Mds&mds mpn
This document provides an overview of myelodysplastic syndromes (MDS). MDS are a heterogeneous group of stem cell disorders characterized by cytopenias, dysplastic bone marrow, and risk of leukemia development. The FAB classification from 1982 and revised WHO classification from 2001 are discussed. Key points include defining the subtypes of MDS (such as refractory anemia or RA with excess blasts), associated features (including ring sideroblasts and cytogenetic abnormalities), and diagnostic criteria based on blood and bone marrow findings. In particular, the document highlights the isolated del(5q) abnormality associated with 5q- syndrome.
Myeloproliferative disorders
i prepared this from different references, but majority is from Davidson internal medicine and Uptodate
Myeloproliferative disorders
The document discusses various myeloproliferative neoplasms (MPNs) including classic MPNs such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis as well as atypical MPNs. It provides details on the diagnostic criteria, signs and symptoms, genetic mutations involved, and treatment approaches for these different MPNs. Chronic myelogenous leukemia is also examined as it represents a distinct MPN characterized by the Philadelphia chromosome genetic abnormality.
What's hot (20)
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
Medicine 5th year, 5th lecture/part two (Dr. Abdulla Sharief)
Similar to Mds 1
Pre leukemia MDS
The document discusses several pre-leukemic disorders and congenital defects that can progress to acute myeloid leukemia (AML) if not treated. These include myelodysplastic syndrome (MDS), marrow failure syndromes like aplastic anemia, and genetic conditions like Fanconi anemia, dyskeratosis congenita, and Shwachman-Diamond syndrome. MDS is characterized by dysplastic and ineffective hematopoiesis leading to cytopenias. Fanconi anemia results from a DNA repair defect and patients have a high risk of developing AML. Dyskeratosis congenita causes bone marrow failure below age 20 due to telomere dysfunction. Treatment options discussed include hematopoietic
MYELODYSPLASTICSYNDROMES.ppt
The myelodysplastic syndromes (MDS) are a group of diseases characterized by bone marrow failure and abnormalities in the appearance of blood cells. MDS results from mutations in bone marrow stem cells that impair differentiation and increase cell death. While some patients with MDS develop acute leukemia, most do not. MDS is diagnosed based on peripheral blood cytopenias and characteristic dysplastic changes seen in the bone marrow, including ring sideroblasts, hypogranular neutrophils, and micromegakaryocytes. Cytogenetic abnormalities are also important for diagnosis and prognosis. Morphologic evaluation remains key for diagnosis of MDS.
MDS.pptx
Dr. Sunandini Das presented on myelodysplastic syndromes (MDS). Key points include:
MDS are clonal hematopoietic stem cell disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, ineffective hematopoiesis, and increased risk of acute myeloid leukemia. The WHO classification of 2022 defines MDS subtypes based on blast percentage, cytogenetics, and genetic mutations. Prognosis is determined by the IPSS-R which categorizes risk based on cytogenetics, blast percentage, and cytopenias. Treatment depends on risk category and may include growth factors, immunosuppression, chemotherapy, stem cell transplant, or clinical trials.
MYELODYSPLASTIC SYNDROME-3.pptx
Myelodysplastic syndromes are a heterogeneous group of clonal stem cell disorders characterized by bone marrow failure and dysplastic changes in blood cell lineages. They have a tendency to progress to acute myeloid leukemia. Diagnosis involves examining the blood count, bone marrow morphology, blast cell percentage, and genetic analysis. The disease presents with anemia, infection, and bleeding from low blood cell counts.
Myelodesplastic syndrome by haider zaman
Myelodesplastic syndrome presentation may easy for Medical student to know about Myelodesplastic syndrome & its classification and Sign and Symptoms,Genetically Abnormalities in MDS,Diagnosing,Morphological abnormalities in MDSs
Myelodysplasticsyndromes
This document provides an overview of myelodysplastic syndrome (MDS). It discusses the history and evolving definitions of MDS. Key points include that MDS is a heterogeneous group of stem cell disorders characterized by cytopenias, dysplasia, and risk of acute myeloid leukemia. The document reviews classification systems including FAB and WHO criteria. It covers pathogenesis, clinical features, risk factors, diagnostic evaluation including blood and bone marrow findings, and molecular abnormalities associated with MDS.
Myelodysplastic syndrome
quite updated according to recent guidelines..covers all aspects to it...recent advances, classification and management.
Childhood mds unlocking the old mystery
This patient presented with pancytopenia and was found to have a hypocellular bone marrow with dysplastic megakaryocytes, decreased myeloid and erythroid lineages, and megaloblastic erythropoiesis. Cytogenetics revealed monosomy 7, which was also present in his half-sister with AML. He was diagnosed with familial monosomy 7 syndrome associated with childhood myelodysplastic syndrome, a rare autosomal dominant condition with variable penetrance. The molecular mechanism is uncertain but the mother is an obligate carrier given the siblings had different fathers.
myeloid malignancy overview
This document provides an overview of the myeloid malignancies, including myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML). It describes key characteristics of each condition, such as increased mature cells in MPNs, decreased blood cells in MDS, and presence of immature cells in AML. Diagnostic criteria and classification systems for AML, including the 2008 WHO classification, are reviewed. Risk stratification in AML and standard treatment approaches are also summarized. Two clinical cases are then presented and discussed in detail.
Haematopathology: An introduction to the various myeloid cell neoplasms
Haematopathology: An introduction to the various myeloid cell neoplasmsQatar Cardiovascular Research Centre
The second in a series of presentations looking at the various neoplasms of the myeloid cell lines in the bone marrow, circulation and solid tumours.MDS 1.pptx
This document provides an overview of myelodysplastic syndrome (MDS). Key points include:
- MDS is a group of bone marrow disorders characterized by low blood cell counts, dysplastic changes in the bone marrow, and a risk of developing acute myeloid leukemia.
- It primarily affects older adults but can occur in younger patients as well. Risk factors include prior chemotherapy/radiation exposure, smoking, and certain genetic conditions.
- The disease involves malignant transformation of myeloid stem cells. Common genetic mutations impact DNA methylation and gene expression regulation.
- Patients present with anemia and related symptoms. Diagnosis involves blood and bone marrow tests showing dysplastic features. Prognosis depends on factors like blast percentage
myelodysplastic_syndromes.ppt
This document provides a history and overview of myelodysplastic syndromes (MDS). It describes how MDS was first characterized in the 1930s and named in the 1970s. It outlines the six main types of MDS according to the WHO classification system and related syndromes. It covers clinical features, etiology, prognostic scoring systems, characteristics of the main MDS subtypes, and treatment approaches for MDS.
Myelodysplastic Syndrome.pptx
Myelodysplastic syndrome (MDS) is a group of clonal hematopoietic stem cell diseases characterized by cytopenia in at least one lineage, dysplasia in one or more myeloid lineages, and a risk of progression to acute myeloid leukemia. The WHO classification system categorizes MDS based on cytopenias, dysplasia, bone marrow blast percentage, and genetic abnormalities. Treatment involves managing symptoms such as anemia, treating underlying causes, and in some cases allogeneic stem cell transplantation. Prognosis depends on disease subtype and risk factors like cytogenetics and bone marrow blast percentage.
Myelodysplastic Syndromes
Myelodysplastic syndromes are a group of stem cell disorders characterized by ineffective hematopoiesis and maturation defects leading to cytopenias. The marrow is usually hypercellular or normocellular but shows cytopenias in the peripheral blood. MDS has various subtypes and risks of transforming to acute myeloid leukemia. Treatment options include supportive care, hypomethylating agents, lenalidomide, and allogeneic stem cell transplant which offers the only potential for cure. Prognosis depends on disease subtype and risk factors as assessed by prognostic scoring systems.
Chapter16
This document contains 4 tables that classify and describe myelodysplastic syndromes (MDS). Table 16.1 describes the World Health Organization classification of MDS subtypes based on peripheral blood and bone marrow findings. Table 16.2 lists common cytogenetic abnormalities in MDS. Table 16.3 classifies MDS into lower and higher risk groups based on survival time and risk of acute myeloid leukemia transformation. Table 16.4 describes myelodysplastic/myeloproliferative neoplasms, a subtype of MDS characterized by features of both myelodysplasia and myeloproliferation.
20160219 - A. Mazzone - Anemie Definizione Prevalenza - Anemie e sindromi mie...
This document summarizes key points about the World Health Organization (WHO) classification of myelodysplastic syndromes (MDS). It outlines the prerequisite and decisive criteria for an MDS diagnosis, including constant cytopenia in one or more lineages and the presence of at least one of dysplasia, blasts between 5-19%, or a characteristic chromosomal abnormality. Differential diagnoses are also discussed. Morphological criteria for dysplasia and blast assessment are defined. Guidelines are provided on evaluating peripheral blood smears, bone marrow aspirates, and trephine biopsies. Minimal diagnostic criteria require over 10% dysplastic cells in one lineage.
Leukemia
Leukaemia is a progressive neoplastic disease characterized by unregulated proliferation of immature blood cells. The main types are acute and chronic leukaemia. Acute leukaemia has a rapid onset and is more aggressive, while chronic leukaemia has a gradual onset and is less aggressive. Leukaemia is further classified as lymphoid or myeloid depending on the origin of the leukemic stem cell clone. Acute myeloid leukaemia is composed of immature myeloid cells and causes bone marrow failure, while acute lymphoid leukaemia is composed of immature lymphoid cells and most commonly affects children.
Chronic Eosinophilia Leukemia (CEL), Keganasan PMN
This document discusses myeloproliferative disorders, which are clonal stem cell disorders characterized by overproduction of one or more myeloid cell lines. The common bcr-abl negative myeloproliferative disorders discussed are polycythemia vera, essential thrombocythemia, and myelofibrosis. JAK2 mutations are involved in the pathogenesis of many of these disorders. The document also discusses mast cell disease, hypereosinophilia, and other related rare conditions.
Acute leukaemia
acute leukemia
For More Medicine Free PPT - http://playnever.blogspot.com/
For Health benefits and medicine videos Subscribe youtube channel - https://www.youtube.com/playlist?list=PLKg-H-sMh9G01zEg4YpndngXODW2bq92w
Similar to Mds 1 (19)
Haematopathology: An introduction to the various myeloid cell neoplasms
Haematopathology: An introduction to the various myeloid cell neoplasms
20160219 - A. Mazzone - Anemie Definizione Prevalenza - Anemie e sindromi mie...
20160219 - A. Mazzone - Anemie Definizione Prevalenza - Anemie e sindromi mie...
Chronic Eosinophilia Leukemia (CEL), Keganasan PMN
Chronic Eosinophilia Leukemia (CEL), Keganasan PMN
More from ariva zhagan
Complement system
The complement system is a collection of soluble proteins and membrane receptors that function in host defense against microbes and inflammatory reactions. It consists of more than 20 proteins numbered C1 through C9. The complement system works through three pathways - classical, lectin, and alternative - that ultimately activate C3 and C5 convertases, cleaving C3 and C5 into fragments that opsonize pathogens, induce inflammation, and form the membrane attack complex to lyse microbes. Complement activation is tightly regulated by inhibitory proteins to prevent damage to host cells. Deficiencies in complement proteins can increase susceptibility to certain infections.
Phagocytosis
Phagocytosis is the process by which leukocytes and macrophages eliminate microbes and dead cells. It involves recognition of the microbes or dead cells by phagocytic receptors, attachment, engulfment through pseudopod formation and plasma membrane extension, and killing through reactive oxygen species, reactive nitrogen species, and lysosomal enzymes released inside the phagosome. Antioxidants and anti-proteases help regulate the killing process.
Free radical injury
Free radicals are highly reactive chemical entities with unpaired electrons that can be toxic under some conditions. There are several types of free radicals including oxygen, sulfur, carbon, and nitrogen centered radicals. Free radicals are formed by either losing or gaining a single electron from a non-radical species and play a role in oxidative stress through reactions like the Fenton reaction.
Cell injury
Cell injury can be reversible or irreversible. Reversible injury results in cellular swelling and fat accumulation but the cell can return to normal function. Irreversible injury leads to necrosis and apoptosis and the cell cannot be treated or recover. Reversible injury is caused by a lack of oxygen or chemicals and results in cellular swelling and fatty changes visible as lipid vacuoles in the cytoplasm. Irreversible injury is caused by prolonged stress and results in cell death.
Cellular unit in health disease
This document discusses the key functions and components of healthy cells, including metabolism, organelles, cytoskeleton, cell-cell interactions, growth factors and receptors, the cell cycle, and stem cells. It explains that cells rely on fundamental housekeeping functions like nutrient production and transport, communication, movement, renewal, and waste breakdown. Specific organelles support metabolism, energy generation, protein synthesis, steroid synthesis, protein modification, and cellular regulation. The cytoskeleton, composed of actin, intermediate filaments and microtubules, gives cells their shape and ability to move. Growth factors stimulate genes for cell growth and division. The tightly regulated cell cycle results in cell division through development and tissue maintenance. Stem cells can differentiate and renew
Special stains in dermato pathology - final copy
This document provides an overview of various special stains used in dermatopathology. It begins by explaining what stains are and their uses, such as enhancing contrast and examining tissues. It then describes the major categories of stains including those for carbohydrates, lipids, microorganisms, connective tissues, and minerals. Specific stains are also outlined, like PAS for glycogen and fungi, Masson's Trichrome for collagen, and Gram staining for bacteria identification. The document concludes by stating several stains used for visualizing structures like mast cells, amyloid, and various microbes under the microscope.
Role of ihc on soft tissue tumours
This document discusses the role of immunohistochemistry (IHC) in diagnosing soft tissue tumours. It begins by defining soft tissue and the WHO classification of soft tissue tumours. IHC is an important ancillary technique that can be used to identify discrete tissue components using antigen-antibody binding. The document outlines the IHC protocol and discusses various markers that can help diagnose different types of soft tissue tumours, including markers for fibroblastic, adipocytic, vascular, neural, osseous and cartilaginous tumours. Specific markers and the tumours they are useful for identifying are provided. The document emphasizes that IHC should be used along with other techniques as markers sometimes show cross-reactivity.
Renal failure
This document summarizes various types of renal failure including acute renal failure and chronic kidney disease. It discusses the etiology, pathogenesis and phases of acute tubular necrosis. It also covers chronic glomerulonephritis and specific conditions like membranous nephropathy, membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, IgA nephropathy, and diabetic nephropathy. The document provides details on urine analysis findings, histopathology techniques like immunofluorescence and electron microscopy in the evaluation of renal diseases.
Processing of tissue
This document describes the steps involved in tissue processing from fixation to embedding in wax. It discusses obtaining fresh specimens, fixation in formalin, dehydration through an alcohol series, clearing in xylene, infiltration and embedding in paraffin wax. Sections are then cut on a microtome, mounted on slides and stained, usually with hematoxylin and eosin, to visualize tissue structures microscopically. Proper processing is important to preserve tissue morphology and produce high quality stained sections for diagnostic examination.
Poorly differentiated neoplasms
This document discusses poorly differentiated neoplasms and provides details about medulloblastoma and meningioma. It notes that medulloblastoma is the most common poorly differentiated brain tumor in children, occurring in the cerebellum. Meningiomas predominantly arise from meningeal cells and can be benign or atypical/anaplastic. The document also covers prion diseases like Creutzfeldt-Jakob disease, which causes rapid dementia and is characterized by spongiform changes in the brain due to misfolded prion proteins.
Polycythemia
Polycythemia is a blood disorder characterized by an increased red blood cell count. There are two main types: primary polycythemia vera, which is a stem cell cancer caused by a JAK2 mutation; and secondary polycythemia, caused by inappropriate erythropoietin secretion in response to conditions like high altitudes or lung/heart diseases. Polycythemia vera symptoms include headache, itching, fatigue and bleeding risks. Diagnosis involves blood tests showing increased red blood cells, hematocrit, and hemoglobin levels along with a bone marrow biopsy. Treatment focuses on phlebotomy and medications to reduce red blood cell counts.
Pem
Nutritional disease can result from protein energy malnutrition (PEM), which is caused by inadequate intake of proteins and calories. PEM leads to deficiencies in digestion/absorption and loss of fat, muscle tissue, and weight. It has multiple etiologies including poverty, infections, illness, alcoholism, and ignorance. PEM is a serious, often lethal condition especially in children under 5 years old. It is diagnosed by body mass index, skin fold thickness, mid-arm circumference, and serum proteins. The two main types are marasmus, characterized by weight loss and depletion of muscle, and kwashiorkor, which occurs when protein deprivation exceeds calorie deficit and results in edema, skin lesions, and fatty liver.
Peadiatric infections
This document lists various pediatric infections organized by the body system affected. It includes respiratory infections caused by adenovirus, rhinovirus, and influenza that can cause upper and lower respiratory tract infections. It also lists digestive infections such as mumps, rotavirus, norovirus, and hepatitis viruses that can cause gastroenteritis. Additionally, it mentions systemic infections affecting the skin like measles, rubella, and varicella zoster that cause rubeola, German measles, and chickenpox/shingles.
Pathology definitions
This document defines key terms related to pathology including types of cell changes (hypertrophy, hyperplasia, atrophy, metaplasia), types of cell death (necrosis, apoptosis, autophagy), inflammation processes (leukocyte recruitment, chemotaxis, reactive oxygen species), immunity and hypersensitivity reactions, neoplasia and tumor characteristics (anaplasia, metastasis), and hematologic disorders (anemia, leukemias, myelodysplastic syndromes).
Paroxysmal nocternal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder caused by a genetic defect involving the PIGA gene. This results in a lack of certain proteins that normally protect red blood cells from being destroyed by the immune system. During sleep, when pressures in blood vessels are lower, the red blood cells are more vulnerable to destruction, leading to hemoglobin in the urine and anemia. Diagnosis involves blood and urine tests and can be confirmed via flow cytometry. Treatment options include stem cell transplantation.
Paraneoplastic syndrome
A paraneoplastic syndrome is a disease or symptom that is caused by cancer but is not due to direct involvement of cancer cells. They occur in 10-15% of cancer patients and are typically seen in lung, breast, ovarian, and lymphoma cancers. Paraneoplastic syndromes can be endocrine, neurological, mucocutaneous, or hematological in nature. Common endocrine paraneoplastic syndromes include Cushing syndrome, SIADH, hypercalcemia, hypoglycemia, polycythemia, hyperaldosteronism, and carcinoid syndrome, which result from hormones or cytokines secreted by tumor cells.
Ovarian neoplasms
This document discusses ovarian germ cell tumors. It describes that germ cell tumors constitute 15-20% of ovarian tumors and are derived from primitive germ cells. They are classified as mature teratomas, immature teratomas, or monodermal tumors. Mature teratomas are benign cysts containing tissues from all germ layers, while immature teratomas are malignant with embryonic or fetal tissues. Specific germ cell tumors discussed include dermoid cysts, dysgerminomas, yolk sac tumors, and choriocarcinomas. Risk factors, morphology, microscopy, and other characteristics are provided for each tumor type.
Nutritional disease
Nutritional disease refers to protein energy malnutrition (PEM), which results from inadequate intake of proteins and calories. PEM causes deficiencies in digestion and absorption, resulting in loss of fat, muscle tissue, weight loss and general weakness. PEM is a serious and often lethal condition, especially in children under 5 years old. It has various etiologies including poverty, infections, illness, alcoholism and dietary restrictions. PEM is diagnosed using measurements like body mass index, mid-arm circumference and serum protein levels. The two main types are marasmus, characterized by weight loss and muscle depletion, and kwashiorkor, distinguished by edema and hypoalbuminemia.
Myeloproliferative disorder
This document discusses myeloproliferative disorders (MPDs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. MPDs are clonal stem cell disorders characterized by excessive proliferation of one or more myeloid cell lineages. Common features include increased proliferation, extramedullary hematopoiesis, marrow fibrosis, and peripheral blood cytopenias. The document then provides more detailed descriptions of polycythemia vera, essential thrombocythemia, and primary myelofibrosis, including their definitions, pathogeneses involving mutations, morphologies, clinical features, complications, investigations, and treatments.
Molecular genetic diagnosis
This document discusses molecular genetic diagnosis techniques. It begins by describing how techniques like karyotyping, Southern blotting, and Sanger sequencing revolutionized genetic diagnosis in the late 20th century. It then covers the various indications for genetic testing, including inherited conditions, prenatal testing, and acquired conditions like cancer. The rest of the document details specific molecular analysis techniques used, such as PCR, Sanger sequencing, pyrosequencing, restriction fragment length analysis, FISH, MLPA, Southern blotting, and next generation sequencing. It provides examples of the medical applications of these various techniques.
More from ariva zhagan (20)
Recently uploaded
Bossa N’ Roll Records by Ismael Vazquez.
Bossa N Roll Records presentation by Izzy Vazquez for Music Retail and Distribution class at Full Sail University
Geography as a Discipline Chapter 1 __ Class 11 Geography NCERT _ Class Notes...
Geography as discipline
Chapter wise All Notes of First year Basic Civil Engineering.pptx
Chapter wise All Notes of First year Basic Civil Engineering
Syllabus
Chapter-1
Introduction to objective, scope and outcome the subject
Chapter 2
Introduction: Scope and Specialization of Civil Engineering, Role of civil Engineer in Society, Impact of infrastructural development on economy of country.
Chapter 3
Surveying: Object Principles & Types of Surveying; Site Plans, Plans & Maps; Scales & Unit of different Measurements.
Linear Measurements: Instruments used. Linear Measurement by Tape, Ranging out Survey Lines and overcoming Obstructions; Measurements on sloping ground; Tape corrections, conventional symbols. Angular Measurements: Instruments used; Introduction to Compass Surveying, Bearings and Longitude & Latitude of a Line, Introduction to total station.
Levelling: Instrument used Object of levelling, Methods of levelling in brief, and Contour maps.
Chapter 4
Buildings: Selection of site for Buildings, Layout of Building Plan, Types of buildings, Plinth area, carpet area, floor space index, Introduction to building byelaws, concept of sun light & ventilation. Components of Buildings & their functions, Basic concept of R.C.C., Introduction to types of foundation
Chapter 5
Transportation: Introduction to Transportation Engineering; Traffic and Road Safety: Types and Characteristics of Various Modes of Transportation; Various Road Traffic Signs, Causes of Accidents and Road Safety Measures.
Chapter 6
Environmental Engineering: Environmental Pollution, Environmental Acts and Regulations, Functional Concepts of Ecology, Basics of Species, Biodiversity, Ecosystem, Hydrological Cycle; Chemical Cycles: Carbon, Nitrogen & Phosphorus; Energy Flow in Ecosystems.
Water Pollution: Water Quality standards, Introduction to Treatment & Disposal of Waste Water. Reuse and Saving of Water, Rain Water Harvesting. Solid Waste Management: Classification of Solid Waste, Collection, Transportation and Disposal of Solid. Recycling of Solid Waste: Energy Recovery, Sanitary Landfill, On-Site Sanitation. Air & Noise Pollution: Primary and Secondary air pollutants, Harmful effects of Air Pollution, Control of Air Pollution. . Noise Pollution Harmful Effects of noise pollution, control of noise pollution, Global warming & Climate Change, Ozone depletion, Greenhouse effect
Text Books:
1. Palancharmy, Basic Civil Engineering, McGraw Hill publishers.
2. Satheesh Gopi, Basic Civil Engineering, Pearson Publishers.
3. Ketki Rangwala Dalal, Essentials of Civil Engineering, Charotar Publishing House.
4. BCP, Surveying volume 1
How to Predict Vendor Bill Product in Odoo 17
This slide will guide us through the process of predicting vendor bill products based on previous purchases from the vendor in Odoo 17.
Traditional Musical Instruments of Arunachal Pradesh and Uttar Pradesh - RAYH...
Traditional Musical Instruments of Arunachal Pradesh and Uttar Pradesh
Beyond Degrees - Empowering the Workforce in the Context of Skills-First.pptx
Iván Bornacelly, Policy Analyst at the OECD Centre for Skills, OECD, presents at the webinar 'Tackling job market gaps with a skills-first approach' on 12 June 2024
Educational Technology in the Health Sciences
Plenary presentation at the NTTC Inter-university Workshop, 18 June 2024, Manila Prince Hotel.
RHEOLOGY Physical pharmaceutics-II notes for B.pharm 4th sem students
Physical pharmaceutics notes for B.pharm students
Jemison, MacLaughlin, and Majumder "Broadening Pathways for Editors and Authors"
Jemison, MacLaughlin, and Majumder "Broadening Pathways for Editors and Authors"National Information Standards Organization (NISO)
This presentation was provided by Racquel Jemison, Ph.D., Christina MacLaughlin, Ph.D., and Paulomi Majumder. Ph.D., all of the American Chemical Society, for the second session of NISO's 2024 Training Series "DEIA in the Scholarly Landscape." Session Two: 'Expanding Pathways to Publishing Careers,' was held June 13, 2024.Mule event processing models | MuleSoft Mysore Meetup #47
Mule event processing models | MuleSoft Mysore Meetup #47
Event Link:- https://meetups.mulesoft.com/events/details/mulesoft-mysore-presents-mule-event-processing-models/
Agenda
● What is event processing in MuleSoft?
● Types of event processing models in Mule 4
● Distinction between the reactive, parallel, blocking & non-blocking processing
For Upcoming Meetups Join Mysore Meetup Group - https://meetups.mulesoft.com/mysore/YouTube:- youtube.com/@mulesoftmysore
Mysore WhatsApp group:- https://chat.whatsapp.com/EhqtHtCC75vCAX7gaO842N
Speaker:-
Shivani Yasaswi - https://www.linkedin.com/in/shivaniyasaswi/
Organizers:-
Shubham Chaurasia - https://www.linkedin.com/in/shubhamchaurasia1/
Giridhar Meka - https://www.linkedin.com/in/giridharmeka
Priya Shaw - https://www.linkedin.com/in/priya-shaw
BÀI TẬP BỔ TRỢ TIẾNG ANH LỚP 9 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2024-2025 - ...
BÀI TẬP BỔ TRỢ TIẾNG ANH LỚP 9 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2024-2025 - ...Nguyen Thanh Tu Collection
https://app.box.com/s/tacvl9ekroe9hqupdnjruiypvm9rdaneWound healing PPT
This document provides an overview of wound healing, its functions, stages, mechanisms, factors affecting it, and complications.
A wound is a break in the integrity of the skin or tissues, which may be associated with disruption of the structure and function.
Healing is the body’s response to injury in an attempt to restore normal structure and functions.
Healing can occur in two ways: Regeneration and Repair
There are 4 phases of wound healing: hemostasis, inflammation, proliferation, and remodeling. This document also describes the mechanism of wound healing. Factors that affect healing include infection, uncontrolled diabetes, poor nutrition, age, anemia, the presence of foreign bodies, etc.
Complications of wound healing like infection, hyperpigmentation of scar, contractures, and keloid formation.
Recently uploaded (20)
Geography as a Discipline Chapter 1 __ Class 11 Geography NCERT _ Class Notes...
Geography as a Discipline Chapter 1 __ Class 11 Geography NCERT _ Class Notes...
Chapter wise All Notes of First year Basic Civil Engineering.pptx
Chapter wise All Notes of First year Basic Civil Engineering.pptx
SWOT analysis in the project Keeping the Memory @live.pptx
SWOT analysis in the project Keeping the Memory @live.pptx
Traditional Musical Instruments of Arunachal Pradesh and Uttar Pradesh - RAYH...
Traditional Musical Instruments of Arunachal Pradesh and Uttar Pradesh - RAYH...
Beyond Degrees - Empowering the Workforce in the Context of Skills-First.pptx
Beyond Degrees - Empowering the Workforce in the Context of Skills-First.pptx
RHEOLOGY Physical pharmaceutics-II notes for B.pharm 4th sem students
RHEOLOGY Physical pharmaceutics-II notes for B.pharm 4th sem students
Jemison, MacLaughlin, and Majumder "Broadening Pathways for Editors and Authors"
Jemison, MacLaughlin, and Majumder "Broadening Pathways for Editors and Authors"
Mule event processing models | MuleSoft Mysore Meetup #47
Mule event processing models | MuleSoft Mysore Meetup #47
BÀI TẬP BỔ TRỢ TIẾNG ANH LỚP 9 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2024-2025 - ...
BÀI TẬP BỔ TRỢ TIẾNG ANH LỚP 9 CẢ NĂM - GLOBAL SUCCESS - NĂM HỌC 2024-2025 - ...
Mds 1
- 3. Definition Clonal hematopoietic stem cell disorders characterized by cytopenias, dysplasia in one or more of the major myeloid cell lines, ineffective hematopoiesis with cellular marrow and risk for leukemic transformation.
- 4. 1. Bone marrow cannot produce blood cells effectively 2. If produced the blood cells will be defective in nature 3. These abnormal cells usually destroyed before they leave from bone marrow or shortly after entering into the blood stream
- 5. 1. Varying degree of tri lineage cytopenias 2. Dysplasia 3. Normocellular or Hypercellular Bone marrow 4. May progress to acute leukemia's
- 6. Incidence 1. Disease of elderly 2. Median age is 65 years 3. M>F 4. Incidence 1/1000/years > 60 years
- 7. PREDISPOSING FACTORS HEREDITARY 1. Down’s syndrome 2. NF 3. Congenital Neutropenia 4. Fanconi’s anemia 5. Shwachman Diamond syndrome 6. Diamond Blackfan syndrome ACQUIRED 1. Radiation 2. Mutation 3. Alkylating agents 4. Tabacoo 5. Benzene 6. Aplastic anemia 7. PNH
- 9. FAB CLASSIFIACTION SUB TYPE PS BM RA Blasts < 1% Blasts < 5% RS < 15% RA – RS Blasts < 1% Blasts < 5% RS > 15% RAEB Blasts < 5% Blasts 5-20% RAEBT Blasts > 5% Blasts 20-30% Auer rods CMML Blasts < 5% Monocyte > 1% Any of the above AML Variable Blasts > 30%
- 10. WHO CLASSIFICATION SUBTYPE PS BM RCUD Unicytopenia / No blast Unilineage dysplasia > 10% of cells Blasts < 5% RS < 15% RARS Anemia Erythroid hyperplasia with Dyserythropoiesis RS > 15% Blasts < 5% RCMD Bi / Pancytopenia No blast / No Auer rods Dysplasia >10 % in > 2 lineage Blast <5% RS > 15% RAEB-1 <5% blasts Bi / Pancytopenia No Auer Rods 5-9% blasts No Auer rods Dysplasia > 1 hematopoietic cell line RAEB-2 5-9% blasts Cytopenias Auer rods 10-19% blasts Auer rod + Myelodysplasia > 1 line
- 11. MDS – U No blasts Cytopenias only < 5% blasts Cytogenetic abnormalities Granulocytic or Megakaryocytic dysplasia MDS – 5q deletion < 1% blasts Anemia Increased platelets < 5% blasts Isolated 5q deletion No Auer rods CMDS < 2 % blasts Dysplastic changes in > 10 % of neutrophils Dysplasia > 10% erythroid precursors Dysplasia > 10% granulocytic precursors
- 12. Etio pathogenesis 1. Denovo 2. Therapy related
- 13. Characteristic features 1. Dyserythropoiesis 2. Dysmyelopoiesis 3. Dysmegakaryopoiesis 4. Ring sideroblast 5. Type I & II blast
- 14. PERIPHERAL SMEAR Erythroid • Ovalocytosis • Macrocytosis • Eliptocytosis • Tear drop cells • Nucleated red cells • Basophilic stippling • Howell –Jolly bodies Myeloid • Pseudo – Pelger Huet anomaly • Auer rod • Hypogranulation • Hypersegmentation of nuclei Megakaryocyte • Giant platelets • Hypogranular platelets • Agranullar platelets
- 15. Bone marrow Erythroid • Megaloblastic erythropoiesis • Nuclear budding • Ring sideroblast • Internuclear bridging • Nuclear fragments • Multinucleation Myeloid • Defective granulation • Hypolobation • Auer rods • Maturation arrest • ALIP Megakaryocyte • Micromegakaryocyte • Hypogranulation • Hypolobation • Multiple small nuclei
- 19. Clinical presentation 1. Anemia 2. Lethargy 3. Weakness 4. Fainting 5. Palpitation 6. Dizziness 7. Headache 8. Menstrual abnormalities 9. Poor appetite 10.Irritability
- 23. Treatment 1. Supportive therapy 2. Chemotherapy 3. Bone marrow transplantation